![]() |
||||||
|
![]() | Fusion Gene Summary |
![]() | Fusion Gene ORF analysis |
![]() | Fusion Genomic Features |
![]() | Fusion Protein Features |
![]() | Fusion Gene Sequence |
![]() | Fusion Gene PPI analysis |
![]() | Related Drugs |
![]() | Related Diseases |
Fusion gene:ELL-CISD3 (FusionGDB2 ID:HG8178TG284106) |
Fusion Gene Summary for ELL-CISD3 |
![]() |
Fusion gene information | Fusion gene name: ELL-CISD3 | Fusion gene ID: hg8178tg284106 | Hgene | Tgene | Gene symbol | ELL | CISD3 | Gene ID | 8178 | 284106 |
Gene name | elongation factor for RNA polymerase II | CDGSH iron sulfur domain 3 | |
Synonyms | C19orf17|ELL1|MEN|PPP1R68 | MiNT|Miner2 | |
Cytomap | ('ELL')('CISD3') 19p13.11 | 17q12 | |
Type of gene | protein-coding | protein-coding | |
Description | RNA polymerase II elongation factor ELLELL gene (11-19 lysine-rich leukemia gene)ELL/KMT2A fusionELL/KMT2A fusion proteinKMT2A/ELL fusionKMT2A/ELL fusion proteineleven-nineteen lysine-rich leukemia proteinelongation factor RNA polymerase IIprotein | CDGSH iron-sulfur domain-containing protein 3, mitochondrialmitoNEET related 2mitoNEET-related protein 2mitochondrial inner NEET protein | |
Modification date | 20200319 | 20200313 | |
UniProtAcc | P55199 | P0C7P0 | |
Ensembl transtripts involved in fusion gene | ENST00000262809, ENST00000596124, | ||
Fusion gene scores | * DoF score | 15 X 12 X 11=1980 | 8 X 6 X 5=240 |
# samples | 21 | 10 | |
** MAII score | log2(21/1980*10)=-3.23703919730085 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(10/240*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ELL [Title/Abstract] AND CISD3 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | ELL(18576222)-CISD3(36887013), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | ELL-CISD3 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. ELL-CISD3 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ELL | GO:0010923 | negative regulation of phosphatase activity | 19389623 |
Tgene | CISD3 | GO:0106034 | protein maturation by [2Fe-2S] cluster transfer | 29259115 |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | KIRC | TCGA-B0-4945-01A | ELL | chr19 | 18576222 | - | CISD3 | chr17 | 36887013 | + |
Top |
Fusion Gene ORF analysis for ELL-CISD3 |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-3UTR | ENST00000262809 | ENST00000578573 | ELL | chr19 | 18576222 | - | CISD3 | chr17 | 36887013 | + |
5CDS-3UTR | ENST00000596124 | ENST00000578573 | ELL | chr19 | 18576222 | - | CISD3 | chr17 | 36887013 | + |
Frame-shift | ENST00000262809 | ENST00000439660 | ELL | chr19 | 18576222 | - | CISD3 | chr17 | 36887013 | + |
Frame-shift | ENST00000596124 | ENST00000439660 | ELL | chr19 | 18576222 | - | CISD3 | chr17 | 36887013 | + |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ELL-CISD3 |
![]() |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
ELL | chr19 | 18576221 | - | CISD3 | chr17 | 36887012 | + | 0.000171554 | 0.99982846 |
ELL | chr19 | 18576221 | - | CISD3 | chr17 | 36887012 | + | 0.000171554 | 0.99982846 |
![]() |
![]() |
Top |
Fusion Protein Features for ELL-CISD3 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:18576222/:36887013) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
ELL | CISD3 |
FUNCTION: Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Elongation factor component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III (PubMed:22195968, PubMed:23932780). Specifically required for stimulating the elongation step of RNA polymerase II- and III-dependent snRNA gene transcription (PubMed:23932780). ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre-initiation complex and early elongation. {ECO:0000269|PubMed:16006523, ECO:0000269|PubMed:20159561, ECO:0000269|PubMed:20471948, ECO:0000269|PubMed:22195968, ECO:0000269|PubMed:22252557, ECO:0000269|PubMed:23932780, ECO:0000269|PubMed:8596958}. | FUNCTION: Can transfer its iron-sulfur clusters to the apoferrodoxins FDX1 and FDX2. Contributes to mitochondrial iron homeostasis and in maintaining normal levels of free iron and reactive oxygen species, and thereby contributes to normal mitochondrial function. {ECO:0000269|PubMed:29259115}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ELL-CISD3 |
![]() |
Top |
Fusion Gene PPI Analysis for ELL-CISD3 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ELL-CISD3 |
![]() (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ELL-CISD3 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |